Detalhe da pesquisa
1.
Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial.
Clin Infect Dis
; 76(3): e1177-e1185, 2023 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36164254
2.
Pharmacokinetics, Safety, and Efficacy of an Allometric Miltefosine Regimen for the Treatment of Visceral Leishmaniasis in Eastern African Children: An Open-label, Phase II Clinical Trial.
Clin Infect Dis
; 68(9): 1530-1538, 2019 04 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-30188978
3.
Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme.
Clin Drug Investig
; 37(3): 259-272, 2017 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-28066878
4.
Leishmaniasis in Uganda: historical account and a review of the literature.
Pan Afr Med J
; 18: 16, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25360200
5.
Clinical factors for severity of Plasmodium falciparum malaria in hospitalized adults in Thailand.
PLoS One
; 8(8): e71503, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23951178
6.
Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial.
PLoS Negl Trop Dis
; 6(6): e1674, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22724029